Literature DB >> 2845255

The purified Ca2+ antagonist receptor from skeletal muscle: subunit structure, photoaffinity labeling and endogenous protein kinase activity.

B S Tuana1, B J Murphy, Q Yi.   

Abstract

Tritiated analogues of the Ca2+ channel blockers such as [3H] PN200-110, [3H] verapamil and [3H] diltiazem have been used to identify and isolate Ca2+ antagonist receptors. The Ca2+ antagonist binding sites were solubilized from skeletal muscle transverse tubules with the detergent CHAPS and purified by wheat germ lectin column chromatography and sucrose density gradient centrifugation. The isolated proteins retained their ability to bind the various classes of Ca2+ channel blockers. Polypeptides of 170, 150, 108, 56, and 32 kDa were found to be present in the purified receptor fraction when analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis under non-reducing conditions. The apparent molecular weight of the 170 kDa polypeptide changed to 145 kDa in the presence of reducing agents, as where the apparent molecular weight of the 150, 108, 56 and 32 kDa peptides remained unchanged. An endogenous protein-kinase present in the original membranes, co-purified with the receptor and stimulated the phosphorylation of the 150 and 56 kDa polypeptides in the isolated fraction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845255     DOI: 10.1007/bf00231011

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

1.  Reconstitution of the voltage-sensitive calcium channel purified from skeletal muscle transverse tubules.

Authors:  B M Curtis; W A Catterall
Journal:  Biochemistry       Date:  1986-06-03       Impact factor: 3.162

2.  Purified dihydropyridine-binding site from skeletal muscle t-tubules is a functional calcium channel.

Authors:  V Flockerzi; H J Oeken; F Hofmann; D Pelzer; A Cavalié; W Trautwein
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Purification of the calcium antagonist receptor of the voltage-sensitive calcium channel from skeletal muscle transverse tubules.

Authors:  B M Curtis; W A Catterall
Journal:  Biochemistry       Date:  1984-05-08       Impact factor: 3.162

5.  Identification and characterization of the dihydropyridine-binding subunit of the skeletal muscle dihydropyridine receptor.

Authors:  A H Sharp; T Imagawa; A T Leung; K P Campbell
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

6.  Regulation of canine heart sarcolemmal Ca2+-pumping ATPase by cyclic GMP.

Authors:  J G Church; A K Sen
Journal:  Biochim Biophys Acta       Date:  1983-02

7.  Photoaffinity labelling of the phenylalkylamine receptor of the skeletal muscle transverse-tubule calcium channel.

Authors:  J Striessnig; H G Knaus; M Grabner; K Moosburger; W Seitz; H Lietz; H Glossmann
Journal:  FEBS Lett       Date:  1987-02-23       Impact factor: 4.124

8.  Receptor pharmacology of calcium entry blocking agents.

Authors:  P L Vaghy; J S Williams; A Schwartz
Journal:  Am J Cardiol       Date:  1987-01-23       Impact factor: 2.778

9.  Stereoselective photoaffinity labelling of the purified 1,4-dihydropyridine receptor of the voltage-dependent calcium channel.

Authors:  J Striessnig; K Moosburger; A Goll; D R Ferry; H Glossmann
Journal:  Eur J Biochem       Date:  1986-12-15

10.  Subunit composition of skeletal muscle transverse tubule calcium channels evaluated with the 1,4-dihydropyridine photoaffinity probe, [3H]azidopine.

Authors:  D R Ferry; K Kämpf; A Goll; H Glossmann
Journal:  EMBO J       Date:  1985-08       Impact factor: 11.598

View more
  1 in total

1.  Voltage-dependent potentiation of L-type Ca2+ channels in skeletal muscle cells requires anchored cAMP-dependent protein kinase.

Authors:  B D Johnson; T Scheuer; W A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.